Roger Gunn is Chief Scientific Officer at Imanova which is a translational research company that specialises in applying positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning techniques to improve productivity in early drug development and to help improve disease understanding. He is also Professor of Molecular Neuroimaging in the Division of Brain Sciences at Imperial College London and Visiting Professor in the Department of Biomedical Engineering at the University of Oxford. He is originally an applied mathematician who has held positions in both academia and industry in the UK and North America. His research interests are focused on the application of mathematical biology and molecular imaging techniques to de-risk the development of novel CNS therapies. Dr. Gunn has authored or coauthored over 150 peer reviewed publications and has H Index > 50.